• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

小鼠镰状细胞病中的肠道屏障功能障碍与小肠嗜中性粒细胞炎症、氧化应激和微生物群失调有关。

Intestinal barrier dysfunction in murine sickle cell disease is associated with small intestine neutrophilic inflammation, oxidative stress, and dysbiosis.

作者信息

Lewis Caitlin V, Sellak Hassan, Sawan Mariem A, Joseph Giji, Darby Trevor M, VanInsberghe David, Naudin Crystal R, Archer David R, Jones Rheinallt M, Taylor W Robert

机构信息

Division of Cardiology, Department of Medicine Emory University School of Medicine Atlanta Georgia USA.

Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics Emory University School of Medicine Atlanta Georgia USA.

出版信息

FASEB Bioadv. 2023 Feb 21;5(5):199-210. doi: 10.1096/fba.2022-00121. eCollection 2023 May.

DOI:10.1096/fba.2022-00121
PMID:37151850
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10158626/
Abstract

The intestinal microbiome has emerged as a potential contributor to the severity of sickle cell disease (SCD). We sought to determine whether SCD mice exhibit intestinal barrier dysfunction, inflammation, and dysbiosis. Using the Townes humanized sickle cell mouse model, we found a 3-fold increase in intestinal permeability as assessed via FITC-dextran (4 kDa) assay in SS (SCD) mice compared to AA (wild type) mice ( = 4,  < 0.05). This was associated with 25 to 50% decreases in claudin-1, 3, and 15 and zonula occludens-1 gene expression ( = 8-10,  < 0.05) in the small intestine. Increased Ly6G staining demonstrated more neutrophils in the SS small intestine (3-fold,  = 5,  < 0.05) associated with increased expression of TNFα, IL-17A, CXCL1, and CD68 (2.5 to 5-fold,  = 7-10,  < 0.05). In addition, we observed 30 to 55% decreases in superoxide dismutase-1, glutathione peroxidase-1, and catalase antioxidant enzyme expression ( = 7-8,  < 0.05) concomitant to an increase in superoxide (2-fold,  = 4,  < 0.05). Importantly, all significant observations of a leaky gut phenotype and inflammation were limited to the small intestine and not observed in the colon. Finally, characterization of the composition of the microbiome within the small intestine revealed dysbiosis in SS mice compared to their AA littermates with 47 phyla to species-level significant alterations in amplicon sequence variants. We conclude that the intestinal barrier is compromised in SCD, associated with decreased gene expression of tight junction proteins, enhanced inflammation, oxidative stress, and gut microbiome dysbiosis, all specific to the small intestine.

摘要

肠道微生物群已成为镰状细胞病(SCD)严重程度的一个潜在影响因素。我们试图确定SCD小鼠是否表现出肠道屏障功能障碍、炎症和微生物群失调。使用汤姆斯人源化镰状细胞小鼠模型,我们发现,与AA(野生型)小鼠相比,通过FITC-葡聚糖(4 kDa)检测评估,SS(SCD)小鼠的肠道通透性增加了3倍(n = 4,P < 0.05)。这与小肠中claudin-1、3和15以及闭合蛋白-1基因表达降低25%至50%相关(n = 8 - 10,P < 0.05)。Ly6G染色增加表明SS小肠中的中性粒细胞更多(3倍,n = 5,P < 0.05),这与TNFα、IL-17A、CXCL1和CD68表达增加相关(2.5至5倍,n = 7 - 10,P < 0.05)。此外,我们观察到超氧化物歧化酶-1、谷胱甘肽过氧化物酶-1和过氧化氢酶抗氧化酶表达降低30%至55%(n = 7 - 8,P < 0.05),同时超氧化物增加(2倍,n = 4,P < 0.05)。重要的是,所有关于肠道渗漏表型和炎症的显著观察结果都仅限于小肠,在结肠中未观察到。最后,对小肠内微生物群组成的表征显示,与它们的AA同窝小鼠相比,SS小鼠存在微生物群失调,在扩增子序列变体中有47个门到物种水平的显著改变。我们得出结论,SCD中肠道屏障受损,与紧密连接蛋白的基因表达降低、炎症增强、氧化应激和肠道微生物群失调有关,所有这些都特定于小肠。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af87/10158626/d92d188907b9/FBA2-5-199-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af87/10158626/e19a0792870f/FBA2-5-199-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af87/10158626/47e92e8bcda2/FBA2-5-199-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af87/10158626/b12aa47e0ecf/FBA2-5-199-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af87/10158626/896dc3222f0a/FBA2-5-199-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af87/10158626/d92d188907b9/FBA2-5-199-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af87/10158626/e19a0792870f/FBA2-5-199-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af87/10158626/47e92e8bcda2/FBA2-5-199-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af87/10158626/b12aa47e0ecf/FBA2-5-199-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af87/10158626/896dc3222f0a/FBA2-5-199-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af87/10158626/d92d188907b9/FBA2-5-199-g005.jpg

相似文献

1
Intestinal barrier dysfunction in murine sickle cell disease is associated with small intestine neutrophilic inflammation, oxidative stress, and dysbiosis.小鼠镰状细胞病中的肠道屏障功能障碍与小肠嗜中性粒细胞炎症、氧化应激和微生物群失调有关。
FASEB Bioadv. 2023 Feb 21;5(5):199-210. doi: 10.1096/fba.2022-00121. eCollection 2023 May.
2
Depletion of Intestinal Microbiome Partially Rescues Bone Loss in Sickle Cell Disease Male Mice.肠道微生物组耗竭部分挽救镰状细胞病雄性小鼠的骨丢失。
Sci Rep. 2019 Jun 17;9(1):8659. doi: 10.1038/s41598-019-45270-4.
3
The gut microbiome in sickle cell disease: Characterization and potential implications.镰状细胞病中的肠道微生物组:特征与潜在影响
PLoS One. 2021 Aug 25;16(8):e0255956. doi: 10.1371/journal.pone.0255956. eCollection 2021.
4
27-Hydroxycholesterol contributes to cognitive deficits in APP/PS1 transgenic mice through microbiota dysbiosis and intestinal barrier dysfunction.27-羟基胆固醇通过微生物群失调和肠屏障功能障碍导致APP/PS1转基因小鼠出现认知缺陷。
J Neuroinflammation. 2020 Jun 27;17(1):199. doi: 10.1186/s12974-020-01873-7.
5
Genes modulating intestinal permeability and microbial community are dysregulated in sickle cell disease.调节肠道通透性和微生物群落的基因在镰状细胞病中失调。
Ann Hematol. 2022 May;101(5):1009-1013. doi: 10.1007/s00277-022-04794-y. Epub 2022 Feb 15.
6
Aberrant Gut Microbiome Contributes to Intestinal Oxidative Stress, Barrier Dysfunction, Inflammation and Systemic Autoimmune Responses in MRL/lpr Mice.肠道微生物组的异常变化导致 MRL/lpr 小鼠肠道氧化应激、屏障功能障碍、炎症和全身自身免疫反应。
Front Immunol. 2021 Apr 12;12:651191. doi: 10.3389/fimmu.2021.651191. eCollection 2021.
7
A Direct Link Implicating Loss of SLC26A6 to Gut Microbial Dysbiosis, Compromised Barrier Integrity, and Inflammation.SLC26A6缺失与肠道微生物群失调、屏障完整性受损和炎症之间的直接联系。
Gastroenterology. 2024 Sep;167(4):704-717.e3. doi: 10.1053/j.gastro.2024.05.002. Epub 2024 May 11.
8
Increased intestinal permeability and gut dysbiosis in the R6/2 mouse model of Huntington's disease.亨廷顿病 R6/2 小鼠模型中肠道通透性增加和肠道菌群失调。
Sci Rep. 2020 Oct 26;10(1):18270. doi: 10.1038/s41598-020-75229-9.
9
Modified Gegen Qinlian decoction ameliorated ulcerative colitis by attenuating inflammation and oxidative stress and enhancing intestinal barrier function in vivo and in vitro.加味葛根芩连汤通过减轻体内和体外的炎症和氧化应激以及增强肠道屏障功能来改善溃疡性结肠炎。
J Ethnopharmacol. 2023 Sep 15;313:116538. doi: 10.1016/j.jep.2023.116538. Epub 2023 Apr 21.
10
Prominent role of gut dysbiosis in the pathogenesis of cystic fibrosis-related liver disease in mice.肠道菌群失调在小鼠囊性纤维化相关性肝病发病机制中的突出作用。
J Hepatol. 2024 Sep;81(3):429-440. doi: 10.1016/j.jhep.2024.03.041. Epub 2024 Mar 28.

引用本文的文献

1
NeoGenesis MB-1 with CRISPR Technology Reduces the Effects of the Viruses (Phages) Associated with Acne - Case Report.采用CRISPR技术的新源MB-1减轻与痤疮相关病毒(噬菌体)的影响——病例报告
Integr Med (Encinitas). 2024 Sep;23(4):34-38.
2
The Effects of Resveratrol and Apigenin on Jejunal Oxidative Injury in Ducks and on Immortalized Duck Intestinal Epithelial Cells Exposed to HO.白藜芦醇和芹菜素对鸭空肠氧化损伤及暴露于HO的永生化鸭肠上皮细胞的影响。
Antioxidants (Basel). 2024 May 17;13(5):611. doi: 10.3390/antiox13050611.
3
Gut Microbiota: Potential Therapeutic Target for Sickle Cell Disease Pain and Complications.

本文引用的文献

1
Low-dose ganciclovir ameliorates dextran sulfate sodium-induced ulcerative colitis through inhibiting macrophage STING activation in mice.低剂量更昔洛韦通过抑制小鼠巨噬细胞STING激活改善葡聚糖硫酸钠诱导的溃疡性结肠炎。
Front Pharmacol. 2022 Nov 17;13:1020670. doi: 10.3389/fphar.2022.1020670. eCollection 2022.
2
Pathophysiological characterization of the Townes mouse model for sickle cell disease.镰状细胞病 Townes 小鼠模型的病理生理学特征。
Transl Res. 2023 Apr;254:77-91. doi: 10.1016/j.trsl.2022.10.007. Epub 2022 Oct 30.
3
Association of Gut Microbiota with Inflammatory Bowel Disease and COVID-19 Severity: A Possible Outcome of the Altered Immune Response.
肠道微生物群:镰状细胞病疼痛和并发症的潜在治疗靶点。
Anemia. 2024 Mar 19;2024:5431000. doi: 10.1155/2024/5431000. eCollection 2024.
4
Sickle Cell Disease Update: New Treatments and Challenging Nutritional Interventions.镰状细胞病最新治疗方法及具有挑战性的营养干预措施。
Nutrients. 2024 Jan 15;16(2):258. doi: 10.3390/nu16020258.
5
Gut microbiota dysbiosis alters chronic pain behaviors in a humanized transgenic mouse model of sickle cell disease.肠道微生物失调改变了镰状细胞病人类转基因小鼠模型中的慢性疼痛行为。
Pain. 2024 Feb 1;165(2):423-439. doi: 10.1097/j.pain.0000000000003034. Epub 2023 Sep 21.
肠道微生物群与炎症性肠病和 COVID-19 严重程度的关联:免疫反应改变的可能结果。
Curr Microbiol. 2022 May 5;79(6):184. doi: 10.1007/s00284-022-02877-7.
4
The Age of Next-Generation Therapeutic-Microbe Discovery: Exploiting Microbe-Microbe and Host-Microbe Interactions for Disease Prevention.下一代治疗性微生物发现的时代:利用微生物-微生物和宿主-微生物相互作用预防疾病。
Infect Immun. 2022 May 19;90(5):e0058921. doi: 10.1128/iai.00589-21. Epub 2022 Apr 6.
5
Genes modulating intestinal permeability and microbial community are dysregulated in sickle cell disease.调节肠道通透性和微生物群落的基因在镰状细胞病中失调。
Ann Hematol. 2022 May;101(5):1009-1013. doi: 10.1007/s00277-022-04794-y. Epub 2022 Feb 15.
6
Intestinal pathophysiological abnormalities in steady state and after vaso-occlusive crisis in murine sickle cell disease.稳态时和血管阻塞性危象后小鼠镰状细胞病的肠道病理生理学异常。
Br J Haematol. 2022 Feb;196(3):777-780. doi: 10.1111/bjh.17889. Epub 2021 Oct 10.
7
Dynamic Properties of the Intestinal Ecosystem Call for Combination Therapies, Targeting Inflammation and Microbiota, in Ulcerative Colitis.肠道生态系统的动态特性要求针对炎症和微生物群采用联合疗法治疗溃疡性结肠炎。
Gastroenterology. 2021 Dec;161(6):1969-1981.e12. doi: 10.1053/j.gastro.2021.08.057. Epub 2021 Sep 8.
8
The gut microbiome in sickle cell disease: Characterization and potential implications.镰状细胞病中的肠道微生物组:特征与潜在影响
PLoS One. 2021 Aug 25;16(8):e0255956. doi: 10.1371/journal.pone.0255956. eCollection 2021.
9
Cage and maternal effects on the bacterial communities of the murine gut.笼养和母体效应对鼠肠道细菌群落的影响。
Sci Rep. 2021 May 10;11(1):9841. doi: 10.1038/s41598-021-89185-5.
10
Intestinal barrier dysfunction as a therapeutic target for cardiovascular disease.肠道屏障功能障碍作为心血管疾病的治疗靶点。
Am J Physiol Heart Circ Physiol. 2020 Dec 1;319(6):H1227-H1233. doi: 10.1152/ajpheart.00612.2020. Epub 2020 Sep 28.